| Literature DB >> 31462740 |
Evgeny V Bragin1, Tamara V Azizova2, Maria V Bannikova1, Evgeniya S Grigoryeva1, Nobuyuki Hamada3.
Abstract
Glaucoma is a major cause of visual impairment, and secondary glaucoma manifested as neovascular glaucoma has long been known to occur following high-dose fractionated radiation therapy. In contrast, little is known as to whether ionizing radiation exposure causes primary glaucoma, except that a single study in Japanese atomic bomb survivors has reported a significantly increase risk. Therefore, the effect of lower dose and lower dose rate remains unclear. Here we report that in Russian Mayak Production Association workers occupationally exposed to chronic radiation for prolonged periods, incidence of total primary glaucoma and primary open-angle glaucoma is significantly associated with various non-radiation factors (sex, attained age, and cataract diagnosed prior to glaucoma), but neither with cumulative dose from external γ-rays nor with cumulative neutron dose nor with the unweighted sum of cumulative γ and neutron doses. The present results suggest for the first time that chronic radiation exposure does not cause primary glaucoma, although the analyses need to be made in other cohorts exposed at various dose and dose rate.Entities:
Mesh:
Year: 2019 PMID: 31462740 PMCID: PMC6713741 DOI: 10.1038/s41598-019-48915-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Study cohort characteristics.
| Characteristics | Males | Females | Both |
|---|---|---|---|
| Number of workers included in the cohort | 16,688 | 5,689 | 22,377 |
| Total primary glaucoma cases | 315 | 161 | 476 |
| POAG cases | 307 | 154 | 461 |
| PYR (Total primary glaucoma incidence) | 383,262 | 160,974 | 544,236 |
| PYR (POAG incidence) | 383,188 | 160,874 | 544,062 |
| Mean age at diagnosis of total primary glaucoma (SD), years | 64.6 (8.5) | 69.0 (8.8) | 66.1 (8.8) |
| Mean age at diagnosis of POAG (SD), years | 64.6 (8.4) | 69.4 (8.3) | 66.2 (8.7) |
| Migrated from Ozyorsk as of 31 December 2005 | 7,198 (41.1%) | 2,014 (35.4%) | 9,212 (41.1%) |
| Vital status known as of 31 December 2008, of them: | 15,870 (95.1%) | 5,436 (95.6%) | 21,267 (95.0%) |
| Died | 8,954 (56.4%) | 2,417 (44.5%) | 11,371 (53.5%) |
| Alive | 6,916 (43.6%) | 3,019 (55.5%) | 9,896 (46.5%) |
| Incidence data available | 16,233 (97.3%) | 5,530 (97.2%) | 21,763 (97.3%) |
| Smoking status available, of them: | 15,636 (93.7%) | 5,270 (92.6%) | 20,906 (93.4%) |
| Known data on qualitative parameters of smoking | 11,064 (70.8%) | 5,172 (98.1%) | 16,236 (77.7%) |
| Data on alcohol consumption available | 14,857 (89.0%) | 5,173 (90.9%) | 20,030 (89.5%) |
| Data on hypertension available | 15,110 (90.5%) | 4,984 (87.6%) | 20,094 (89.8%) |
| Data on body mass index | 13,732 (82.3%) | 4,660 (81.9%) | 18,392 (82.2%) |
| Mean age at first employment (SD), years | 24.1 (7.1) | 27.3 (8.0) | 24.9 (7.5) |
| Mean calendar year at first employment (SD), calendar years | 1959.8 (9.8) | 1958.0 (10.4) | 1959.4 (9.8) |
| Mean duration of employment at the Mayak PA (SD), years | 18.3 (14.8) | 17.4 (12.8) | 17.9 (14.1) |
| Mean age at death for workers known to have died (SD), years | 60.2 (13.6) | 68.5 (12.4) | 62.00 (13.8) |
| Mean age of workers known to be alive (SD), years | 66.5 (10.1) | 74.8 (9.3) | 68.8 (11.5) |
| Mean age as of migration date (SD), years | 31.2 (10.2) | 34.2 (11.9) | 31.6 (10.3) |
| Mean cumulative brain absorbed dose from external γ-rays (SD), Gya | 0.46 (0.67) | 0.36 (0.56) | 0.44 (0.65) |
| Workers without neutron exposure | 13,213 (79.2%) | 5,081 (89.3%) | 18,294 (81.8%) |
| Workers with neutron exposure | 3,475 (20.8%) | 608 (10.7%) | 4,083 (18.2%) |
| Mean cumulative brain absorbed dose from neutrons (SD), Gyb | 0.0016 (0.0043) | 0.0016 (0.0050) | 0.0016 (0.0044) |
| The unweighted sum of mean cumulative brain absorbed γ + neutrons dose (SD), Gya | 0.46 (0.67) | 0.37 (0.56) | 0.44 (0.65) |
Notes: POAG, primary open-angle glaucoma. PYR, person years at risk. SD, standard deviation. PA, production association.
aFor all workers.
bFor workers with neutron exposure.
Risk analysis results for primary glaucoma and POAG incidence in relation to non-radiation factors.
| Factors | Total primary glaucoma | POAG | |||||
|---|---|---|---|---|---|---|---|
| RR (95% CI) | Number of cases | RR (95% CI) | Number of cases | ||||
|
| |||||||
| Males | 1 (reference) | 315 | — | 1 (reference) | 307 | — | |
| Females | 0.68 (0.56, 0.82) | 161 | <0.001 | 0.66 (0.54, 0.81) | 154 | <0.001 | |
|
| |||||||
| Males | <40 | — | 0 | — | — | 0 | — |
| 40–45 | 0.02 (0.01, 0.04) | 5 | <0.001 | 0.01 (0.01, 0.03) | 4 | <0.001 | |
| 45–50 | 0.04 (0.02, 0.08) | 12 | <0.001 | 0.04 (0.02, 0.08) | 12 | <0.001 | |
| 50–55 | 0.10 (0.06, 0.15) | 22 | <0.001 | 0.10 (0.06, 0.16) | 22 | <0.001 | |
| 55–60 | 0.27 (0.18, 0.39) | 46 | <0.001 | 0.27 (0.18, 0.39) | 45 | <0.001 | |
| 60–65 | 0.55 (0.39, 0.76) | 67 | <0.001 | 0.55 (0.40, 0.77) | 66 | <0.001 | |
| 65–70 | 1 (reference) | 81 | — | 1 (reference) | 79 | — | |
| 70–75 | 1.46 (1.03, 2.06) | 55 | 0.032 | 1.45 (1.01, 2.05) | 53 | 0.040 | |
| 75–80 | 1.10 (0.63, 1.81) | 18 | >0.50 | 1.14 (0.65, 1.87) | 18 | >0.50 | |
| 80–85 | 1.76 (0.77, 3.49) | 8 | 0.140 | 1.59 (0.66, 3.28) | 7 | 0.252 | |
| ≥85 | 1.00 (0.06, 4.68) | 1 | >0.50 | 1.04 (0.06, 4.83) | 1 | >0.50 | |
| Females | <40 | — | 0 | — | — | 0 | — |
| 40–45 | 0.05 (0.01, 0.15) | 3 | <0.001 | 0.02 (0.01, 0.08) | 1 | <0.001 | |
| 45–50 | 0.07 (0.02, 0.18) | 4 | <0.001 | 0.07 (0.02, 0.17) | 4 | <0.001 | |
| 50–55 | 0.11 (0.04, 0.25) | 6 | <0.001 | 0.07 (0.02, 0.18) | 4 | <0.001 | |
| 55–60 | 0.10 (0.03, 0.23) | 5 | <0.001 | 0.10 (0.03, 0.22) | 5 | <0.001 | |
| 60–65 | 0.66 (0.40, 1.09) | 29 | 0.107 | 0.62 (0.37, 1.02) | 28 | 0.062 | |
| 65–70 | 1 (reference) | 34 | — | 1 (reference) | 35 | — | |
| 70–75 | 1.58 (0.99, 2.53) | 37 | 0.057 | 1.50 (0.93, 2.40) | 36 | 0.093 | |
| 75–80 | 2.23 (1.35, 3.67) | 31 | 0.001 | 1.96 (1.17, 3.25) | 28 | 0.010 | |
| 80–85 | 2.20 (1.01, 4.38) | 10 | 0.033 | 2.38 (1.13, 4.65) | 11 | 0.015 | |
| ≥85 | 1.81 (0.29, 6.25) | 2 | 0.428 | 1.85 (0.29, 6.42) | 2 | 0.410 | |
|
| |||||||
| Males | Unknown | 0.78 (0.47, 1.21) | 19 | 0.294 | 0.75 (0.45, 1.19) | 18 | 0.250 |
| Hypertension-free | 1 (reference) | 247 | — | 1 (reference) | 243 | — | |
| Hypertension | 0.99 (0.72, 1.34) | 49 | >0.50 | 0.95 (0.68, 1.29) | 46 | >0.50 | |
| Females | Unknown | 0.77 (0.41, 1.31) | 13 | 0.360 | 0.81 (0.43, 1.38) | 13 | 0.464 |
| Hypertension-free | 1 (reference) | 129 | — | 1 (reference) | 123 | — | |
| Hypertension | 1.00 (0.60, 1.58) | 19 | >0.50 | 0.99 (0.58, 1.59) | 18 | >0.50 | |
|
| |||||||
| Males | Unknown | 0.97 (0.67, 1.36) | 36 | >0.50 | 0.96 (0.66, 1.37) | 35 | >0.50 |
| BMI < 18.5 kg m−2 | 0.80 (0.20, 2.09) | 3 | >0.50 | 0.81 (0.20, 2.13) | 3 | >0.50 | |
| BMI 18.5–24.9 kg m−2 | 1 (reference) | 232 | — | 1 (reference) | 227 | — | |
| BMI 25–29.9 kg m−2 | 0.77 (0.54, 1.07) | 39 | 0.135 | 0.75 (0.52, 1.04) | 37 | 0.101 | |
| BMI ≥ 30 kg m−2 | 1.09 (0.39, 2.36) | 5 | >0.50 | 1.11 (0.40, 2.42) | 5 | >0.50 | |
| Females | Unknown | 0.83 (0.50, 1.32) | 21 | 0.448 | 0.80 (0.48, 1.29) | 20 | 0.383 |
| BMI < 18.5 kg m−2 | — | 0 | — | — | 0 | — | |
| BMI 18.5–24.9 kg m−2 | 1 (reference) | 83 | — | 1 (reference) | 82 | — | |
| BMI 25–29.9 kg m−2 | 1.08 (0.74, 1.55) | 44 | >0.50 | 1.00 (0.67, 1.44) | 40 | >0.50 | |
| BMI ≥ 30 kg m−2 | 1.21 (0.64, 2.10) | 13 | >0.50 | 1.13 (0.59, 2.00) | 12 | >0.50 | |
|
| |||||||
| Males | Free from DM | 1 (reference) | 293 | — | 1 (reference) | 285 | — |
| Diagnosed with DM | 1.35 (0.85, 2.03) | 22 | 0.182 | 1.39 (0.87, 2.10) | 22 | 0.140 | |
| Females | Free from DM | 1 (reference) | 145 | — | 1 (reference) | 139 | — |
| Diagnosed with DM | 1.26 (0.72, 2.06) | 16 | 0.380 | 1.21 (0.68, 2.00) | 15 | 0.488 | |
|
| |||||||
| Males | Free of cataract | 1 (reference) | 89 | — | 1 (reference) | 85 | — |
| Diagnosed with cataract | 12.09 (9.08, 16.23) | 226 | <0.001 | 12.56 (9.40, 16.95) | 222 | <0.001 | |
| Females | Free of cataract | 1 (reference) | 38 | — | 1 (reference) | 32 | — |
| Diagnosed with cataract | 8.43 (5.54, 13.19) | 123 | <0.001 | 9.45 (6.09, 15.16) | 122 | <0.001 | |
Notes: Bold font, p < 0.05. BMI, body mass index. CI, confidence interval estimated using the profile likelihood. DM, diabetes mellitus. POAG, primary open-angle glaucoma. RR, relative risk. p values are given, assessed via the Wald statistics.
RR of primary glaucoma and POAG incidence by dose from external γ-rays, neutron dose and γ + neutron dose.
| Cumulative dose (Gy), range | Mean cumulative dose (Gy) | Total primary glaucoma | POAG | ||||||
|---|---|---|---|---|---|---|---|---|---|
| PYR | Number of cases | RR (95% CI) | PYR | Number of cases | RR (95% CI) | ||||
|
| |||||||||
| 0–0.25 | 0.06 | 345,381 | 237 | 1 (reference) | — | 345,512 | 228 | 1 (reference) | — |
| 0.25–0.5 | 0.36 | 61,697 | 71 | 0.87 (0.65–1.15) | 0.332 | 61,699 | 70 | 0.88 (0.66–1.17) | 0.391 |
| 0.5–0.75 | 0.62 | 32,775 | 33 | 0.76 (0.50–1.10) | 0.158 | 32,794 | 31 | 0.73 (0.48–1.07) | 0.121 |
| 0.75–1.0 | 0.87 | 23,771 | 35 | 0.90 (0.59–1.32) | >0.50 | 23,800 | 35 | 0.94 (0.62–1.39) | >0.50 |
| 1.0–1.25 | 1.12 | 16,275 | 24 | 0.95 (0.58–1.48) | >0.50 | 16,275 | 24 | 0.99 (0.60–1.56) | >0.50 |
| 1.25–1.5 | 1.37 | 12,744 | 19 | 0.90 (0.51–1.47) | >0.50 | 12,765 | 18 | 0.91 (0.51–1.50) | >0.50 |
| 1.5–2.0 | 1.72 | 17,407 | 33 | 1.22 (0.80–1.81) | 0.344 | 17,409 | 32 | 1.22 (0.79–1.82) | 0.360 |
| ≥2.0 | 2.57 | 15,777 | 24 | 0.89 (0.54–1.39) | >0.50 | 15,778 | 23 | 0.87 (0.53–1.38) | >0.50 |
|
| |||||||||
| 0–0.001 | 0.0004 | 50,538 | 57 | 1 (reference) | — | 50,554 | 56 | 1 (reference) | — |
| 0.001–0.0025 | 0.0016 | 17,990 | 21 | 0.78 (0.41, 1.42) | 0.438 | 17,990 | 21 | 0.83 (0.43, 1.51) | >0.50 |
| 0.0025–0.005 | 0.0034 | 9,112 | 22 | 1.29 (0.65, 2.51) | 0.462 | 9,130 | 21 | 1.20 (0.60, 2.36) | >0.50 |
| 0.005–0.01 | 0.0068 | 2,884 | 3 | 0.34 (0.05, 1.23) | 0.158 | 2,884 | 3 | 0.34 (0.05, 1.22) | 0.157 |
| ≥0.01 | 0.0224 | 1,178 | 3 | 2.06 (0.42, 7.37) | 0.310 | 1,178 | 3 | 2.13 (0.43, 7.73) | 0.292 |
|
| |||||||||
| 0–0.25 | 0.06 | 345,321 | 237 | 1 (reference) | — | 345,441 | 228 | 1 (reference) | — |
| 0.25–0.5 | 0.36 | 61,694 | 71 | 0.86 (0.65, 1.14) | 0.317 | 61,700 | 70 | 0.88 (0.67, 1.17) | 0.394 |
| 0.5–0.75 | 0.62 | 32,727 | 33 | 0.74 (0.50, 1.07) | 0.119 | 32,748 | 31 | 0.72 (0.48, 1.04) | 0.099 |
| 0.75–1.0 | 0.87 | 23,787 | 35 | 0.99 (0.67, 1.41) | >0.50 | 23,817 | 35 | 1.02 (0.69, 1.47) | >0.50 |
| 1.0–1.25 | 1.12 | 16,343 | 24 | 1.02 (0.64, 1.56) | >0.50 | 16,345 | 24 | 1.06 (0.67, 1.61) | >0.50 |
| 1.25–1.5 | 1.37 | 12,744 | 19 | 0.99 (0.59, 1.57) | >0.50 | 12,765 | 18 | 0.97 (0.57, 1.56) | >0.50 |
| 1.5–2.0 | 1.72 | 17,428 | 33 | 1.14 (0.76, 1.67) | >0.50 | 17,430 | 32 | 1.15 (0.75, 1.69) | >0.50 |
| ≥2.0 | 2.57 | 15,783 | 24 | 0.86 (0.53, 1.34) | >0.50 | 15,786 | 23 | 0.84 (0.51, 1.32) | 0.476 |
Notes: stratified by sex, attained age, birth cohort, diagnosed with hypertension, body mass index, diagnosed with diabetes mellitus and neutron dose for external exposure association analysis and vice versa. CI, confidence interval estimated using the profile likelihood. PYR, person-years at risk. RR, relative risk. POAG, primary open-angle glaucoma. p values are given, assessed via the Wald statistics.
aFor all workers.
bFor workers with neutron exposure.
Primary glaucoma and POAG incidence risk with external γ-dose, neutron dose and γ + neutron dose.
| Analysis type | Total primary glaucoma | POAG | ||
|---|---|---|---|---|
| ERR/Gy (95% CI) | ERR/Gy (95% CI) | |||
|
| ||||
| Baseline analysisb, 5 year lag | 0.01 (−0.13, 0.19) | >0.50 | 0.0003 (−0.13, 0.19) | >0.50 |
|
| ||||
| 0 year lag | 0.01 (−0.13, 0.19) | >0.50 | 0.001 (−0.13, 0.19) | >0.50 |
| 10 year lag | 0.002 (−0.13, 0.19) | >0.50 | −0.003 (−0.14, 0.19) | >0.50 |
| 15 year lag | −0.001 (−0.13, 0.19) | >0.50 | −0.005 (−0.14, 0.18) | >0.50 |
| 20 year lag | −0.01 (−0.15, 0.17) | >0.50 | −0.02 (−0.15, 0.17) | >0.50 |
|
| ||||
| By hypertension | −0.01 (−0.13, 0.17) | >0.50 | −0.01 (−0.14, 0.17) | >0.50 |
| By BMI | 0.01 (−0.12, 0.19) | >0.50 | 0.01 (−0.12, 0.20) | >0.50 |
| By diabetes mellitus | 0.03 (−0.11, 0.22) | >0.50 | 0.02 (−0.12, 0.21) | >0.50 |
| By neutron dose | 0.01 (−0.12, 0.20) | >0.50 | 0.01 (−0.13, 0.19) | >0.50 |
|
| ||||
| By smoking index | 0.01 (−0.13, 0.20) | >0.50 | −0.001 (−0.14, 0.20) | >0.50 |
| By smoking and alcohol | 0.07 (−0.10, 0.32) | 0.48 | 0.06 (−0.11, 0.30) | >0.50 |
| By cataract | −0.04 (−0.16, 0.12) | >0.50 | −0.05 (−0.17, 0.11) | 0.46 |
| By cataract surgery | 0.01 (−0.13, 0.20) | >0.50 | 0.004 (−0.13, 0.20) | >0.50 |
|
| ||||
| Males | −0.05 (−0.19, 0.16) | >0.50 | −0.05 (−0.20, 0.15) | >0.50 |
| Females | 0.16 (−0.13, 0.63) | 0.38 | 0.15 (−0.14, 0.63) | 0.42 |
| 0.27 | 0.28 | |||
|
| ||||
| <50 years | 3.24 (−2.41, 61.08) | 0.35 | 1.22 (−1.35, 57.68) | >0.50 |
| 50–59 years | −0.13 (n/a, 0.41) | 0.47 | −0.07 (−0.44, 0.58) | >0.50 |
| 60–69 years | −0.03 (−0.21, 0.26) | >0.50 | −0.02 (−0.20, 0.28) | >0.50 |
| ≥70 years | 0.06 (−0.16, 0.41) | >0.50 | 0.02 (−0.20, 0.37) | >0.50 |
| 0.38 | >0.50 | |||
| 0.49 | >0.50 | |||
|
| ||||
| <30 years | −0.03 (−0.16, 0.18) | >0.50 | −0.03 (−0.17, 0.17) | >0.50 |
| 30–40 years | −0.19 (n/a, 0.71) | 0.23 | −0.18 (n/a, 0.72) | 0.25 |
| ≥40 years | 2.98 (−2.31, 26.99) | 0.28 | 1.81 (−1.55, 17.67) | >0.50 |
| 0.27 | 0.31 | |||
|
| ||||
| Sensitivity analysisg, 5 year lag | 22.83 (−33.20, 150.80) | >0.50 | 23.64 (−33.77, 154.10) | >0.50 |
|
| ||||
| Sensitivity analysish, 5 year lag | 0.01 (−0.12, 0.19) | >0.50 | −0.01 (−0.14, 0.17) | >0.50 |
Notes: BMI, body mass index. DM, diabetes mellitus. ERR, excess relative risk. CI, confidence interval estimated using the profile likelihood. n/a, not available. POAG, primary open-angle glaucoma.
ap values of improvement in fit over null model (with no trend in dose) are given, assessed via the Wald statistics.
bStratified by sex, attained age, birth cohort, diagnosed with hypertension, BMI, diagnosed with DM and neutron dose.
cTested for heterogeneity between males and females, assessed via the likelihood ratio test.
dTested for heterogeneity between groups of workers of different attained age, assessed via the likelihood ratio test.
eTested for a log-linear trend in the ERR/Gy with attained age, assessed via the likelihood ratio test.
fTested for heterogeneity between groups of workers of different age at first employment, assessed via the likelihood ratio test.
gStratified by sex, attained age, birth cohort, diagnosed with hypertension, BMI, diagnosed with DM and dose from external γ-ray.
hStratified by sex, attained age, birth cohort, diagnosed with hypertension, BMI, diagnosed with DM.
iFor all workers.
jFor workers with neutron exposure.
Figure 1Primary glaucoma (a,c,e) and POAG (b,d,f) incidence by cumulative dose from external γ-rays (a,b), neutron dose (c,d) and γ + neutron dose (e,f).
Glaucoma incidence risk following various exposure scenarios.
| Reference, year | Study design | Cohort | Follow-up period | Radiation dose (range) | Number of participants | Number of cases | Findings | Adjustments |
|---|---|---|---|---|---|---|---|---|
| Kiuchi | Screening with the succeeding ophthalmological examination | AHS | 2006–2008 (51–53 years after exposure) | Eye dose 0.57 Gy (0–4.14) | 1589 | Normal-tension POAG: 226 | OR at 1 Gy = 1.31 (95% CIs: 1.11, 1.53, | Sex, age, city, cataract surgery, diabetes mellitus |
| POAG with IOP > 21 mmHg: 36 | OR at 1 Gy = 0.79 (95% CIs: 0.52, 1.21, | |||||||
| PACG: 25 | OR at 1 Gy = 0.54 (95% CIs: 0.29, 1.02, | |||||||
| Kiuchi | Screening with the succeeding ophthalmological examination | AHS | 2006–2008 (51–53 years after exposure) | Mean radiation dose 0.66 Gy (NTG subjects) | 1640 | NTG: 153 | OR at 1 Gy = 1.39 (95% CI: 1.15, 1.69, | Sex. Age, city, smoking, hypertension, dyslipidemia, diabetes, BMI, CRP |
| POAG: 25 | OR at 1 Gy = 0.79 (95% CI: 0.32, 1.82, | |||||||
| PACG: 18 | OR at 1 Gy = 0.44 (95% CI: 0.13, 1.54, | |||||||
| Little | Questionnaire-based screening (self-reported diagnosis) | USRT | 1983–1989 1994–1998 2003–2005 2012–2014 (13.2 years of a mean follow-up per person) | Eye lens dose 0.058 Gy (0.024–0.071) | 69,568 | 1631 | ERR/Gy = −0.57 (95% CIs: −1.46, 0.60, | Sex, ethnicity, year of birth, diabetes mellitus, BMI, smoking status |
| Azizova | Cohort study based on mandatory annual ophthalmological examinations throughout the whole follow-up period | Mayak PA | 1948–2008 (35.7 years of a mean follow-up per person) | Brain absorbed dose from external γ-rays 0.44 Gy (0–8.4) | 22,377 | Primary glaucoma: 476 | ERR/Gy = 0.01 (95% CIs: −0.13, 0.19, | Sex, attained age, birth cohort, hypertension, BMI, DM and neutron dose |
| POAG: 461 | ERR/Gy = 0.0003 (95% CIs: −0.13, 0.19, |
AHS, Adult Health Study. BMI, body mass index, CRP, C-reactive protein. DM, diabetes mellitus. ERR, excess relative risk. IOP, intraocular pressure. OR, odds ratio. PA, Production Association. PACG, primary angle-closure glaucoma. POAG, primary open-angle glaucoma. USRT, US Radiologic Technologists.